Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: Data from the international COMORA cohort

Ihsane Hmamouchi, Kevin Winthrop, Odile Launay, Maxime Dougados

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Rheumatoid Arthritis (RA) patients are at increased risk of suffering from respiratory infections than the general public. Vaccinations against Streptococcus pneumococcus and influenza are recommended, but not often used in RA. Our objectives were: (1) to describe pneumococcal and influenza vaccine coverage in RA patients across various countries and (2) to identify factors associated with their usage. Methods: Using data from the COMORA cohort, 3920 RA patients were enrolled across 17 countries. We collected patient demographic and disease characteristics, and reported vaccine use over a six month time period. We used logistic regression to evaluate factors related to pneumococcal and influenza vaccine coverage. Results: Overall vaccination coverage within the recommendations was low with huge disparities between countries: 17.2% (95%CI: 16.0-18.4) for pneumococcal vaccination (from 0% in Morocco to 56.5% in France) and 25.3% (95%CI: 23.8-26.5) for influenza vaccination (less than 1% in Morocco and Egypt to 66.2% in Japan). In countries where immunization was more frequent, we found that predictive factors of vaccination were older age, lower disease activity, higher educational level, use of biotherapy, absence of corticosteroid therapy, and presence of comorbidities. Conclusion: Despite international recommendations for influenza and pneumococcal vaccination, we observed a low prevalence of these vaccinations among RA patients, with huge disparity between countries. Efforts are needed to better inform patients and physicians regarding the need for vaccinations.

Original languageEnglish (US)
Pages (from-to)1446-1452
Number of pages7
JournalVaccine
Volume33
Issue number12
DOIs
StatePublished - Mar 17 2015

Fingerprint

Pneumococcal Vaccines
rheumatoid arthritis
Influenza Vaccines
influenza
Rheumatoid Arthritis
Vaccination
vaccination
vaccines
Human Influenza
Morocco
Biological Therapy
Egypt
Streptococcus
educational status
adrenal cortex hormones
Streptococcus pneumoniae
physicians
Respiratory Tract Infections
France
Comorbidity

Keywords

  • Comorbidities
  • Influenza
  • Pneumococcus
  • Rheumatoid arthritis
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis : Data from the international COMORA cohort. / Hmamouchi, Ihsane; Winthrop, Kevin; Launay, Odile; Dougados, Maxime.

In: Vaccine, Vol. 33, No. 12, 17.03.2015, p. 1446-1452.

Research output: Contribution to journalArticle

Hmamouchi, Ihsane ; Winthrop, Kevin ; Launay, Odile ; Dougados, Maxime. / Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis : Data from the international COMORA cohort. In: Vaccine. 2015 ; Vol. 33, No. 12. pp. 1446-1452.
@article{9b7a33e28e0949d18ff3f48159a3b28b,
title = "Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: Data from the international COMORA cohort",
abstract = "Rheumatoid Arthritis (RA) patients are at increased risk of suffering from respiratory infections than the general public. Vaccinations against Streptococcus pneumococcus and influenza are recommended, but not often used in RA. Our objectives were: (1) to describe pneumococcal and influenza vaccine coverage in RA patients across various countries and (2) to identify factors associated with their usage. Methods: Using data from the COMORA cohort, 3920 RA patients were enrolled across 17 countries. We collected patient demographic and disease characteristics, and reported vaccine use over a six month time period. We used logistic regression to evaluate factors related to pneumococcal and influenza vaccine coverage. Results: Overall vaccination coverage within the recommendations was low with huge disparities between countries: 17.2{\%} (95{\%}CI: 16.0-18.4) for pneumococcal vaccination (from 0{\%} in Morocco to 56.5{\%} in France) and 25.3{\%} (95{\%}CI: 23.8-26.5) for influenza vaccination (less than 1{\%} in Morocco and Egypt to 66.2{\%} in Japan). In countries where immunization was more frequent, we found that predictive factors of vaccination were older age, lower disease activity, higher educational level, use of biotherapy, absence of corticosteroid therapy, and presence of comorbidities. Conclusion: Despite international recommendations for influenza and pneumococcal vaccination, we observed a low prevalence of these vaccinations among RA patients, with huge disparity between countries. Efforts are needed to better inform patients and physicians regarding the need for vaccinations.",
keywords = "Comorbidities, Influenza, Pneumococcus, Rheumatoid arthritis, Vaccine",
author = "Ihsane Hmamouchi and Kevin Winthrop and Odile Launay and Maxime Dougados",
year = "2015",
month = "3",
day = "17",
doi = "10.1016/j.vaccine.2015.01.065",
language = "English (US)",
volume = "33",
pages = "1446--1452",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "12",

}

TY - JOUR

T1 - Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis

T2 - Data from the international COMORA cohort

AU - Hmamouchi, Ihsane

AU - Winthrop, Kevin

AU - Launay, Odile

AU - Dougados, Maxime

PY - 2015/3/17

Y1 - 2015/3/17

N2 - Rheumatoid Arthritis (RA) patients are at increased risk of suffering from respiratory infections than the general public. Vaccinations against Streptococcus pneumococcus and influenza are recommended, but not often used in RA. Our objectives were: (1) to describe pneumococcal and influenza vaccine coverage in RA patients across various countries and (2) to identify factors associated with their usage. Methods: Using data from the COMORA cohort, 3920 RA patients were enrolled across 17 countries. We collected patient demographic and disease characteristics, and reported vaccine use over a six month time period. We used logistic regression to evaluate factors related to pneumococcal and influenza vaccine coverage. Results: Overall vaccination coverage within the recommendations was low with huge disparities between countries: 17.2% (95%CI: 16.0-18.4) for pneumococcal vaccination (from 0% in Morocco to 56.5% in France) and 25.3% (95%CI: 23.8-26.5) for influenza vaccination (less than 1% in Morocco and Egypt to 66.2% in Japan). In countries where immunization was more frequent, we found that predictive factors of vaccination were older age, lower disease activity, higher educational level, use of biotherapy, absence of corticosteroid therapy, and presence of comorbidities. Conclusion: Despite international recommendations for influenza and pneumococcal vaccination, we observed a low prevalence of these vaccinations among RA patients, with huge disparity between countries. Efforts are needed to better inform patients and physicians regarding the need for vaccinations.

AB - Rheumatoid Arthritis (RA) patients are at increased risk of suffering from respiratory infections than the general public. Vaccinations against Streptococcus pneumococcus and influenza are recommended, but not often used in RA. Our objectives were: (1) to describe pneumococcal and influenza vaccine coverage in RA patients across various countries and (2) to identify factors associated with their usage. Methods: Using data from the COMORA cohort, 3920 RA patients were enrolled across 17 countries. We collected patient demographic and disease characteristics, and reported vaccine use over a six month time period. We used logistic regression to evaluate factors related to pneumococcal and influenza vaccine coverage. Results: Overall vaccination coverage within the recommendations was low with huge disparities between countries: 17.2% (95%CI: 16.0-18.4) for pneumococcal vaccination (from 0% in Morocco to 56.5% in France) and 25.3% (95%CI: 23.8-26.5) for influenza vaccination (less than 1% in Morocco and Egypt to 66.2% in Japan). In countries where immunization was more frequent, we found that predictive factors of vaccination were older age, lower disease activity, higher educational level, use of biotherapy, absence of corticosteroid therapy, and presence of comorbidities. Conclusion: Despite international recommendations for influenza and pneumococcal vaccination, we observed a low prevalence of these vaccinations among RA patients, with huge disparity between countries. Efforts are needed to better inform patients and physicians regarding the need for vaccinations.

KW - Comorbidities

KW - Influenza

KW - Pneumococcus

KW - Rheumatoid arthritis

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84924501441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924501441&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2015.01.065

DO - 10.1016/j.vaccine.2015.01.065

M3 - Article

C2 - 25659279

AN - SCOPUS:84924501441

VL - 33

SP - 1446

EP - 1452

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 12

ER -